Home › Markets › Health Care › XERS

Xeris Biopharma Holdings Inc. (XERS)

XERS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$10.20
-2.49% on the day
Market cap
$1.9B
Small cap
Revenue · 2025
$291.8M
+43.7% on 2024
Net income · 2025
$554K
0.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerXERS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001867096
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$291.8M
Net income$554K
Operating income$24.9M
Net margin0.2%
Operating margin8.5%
Revenue growth+43.7%
Cash$111.0M
Total assets$383.5M
P/E (computed)3356.8×
P/S (computed)6.4×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-03-06
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-08-06
Latest current report8-K2026-10-14
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 334 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.1%
1 month+32.1%
3 months+13.9%
Year to date+26.1%
1 year+24.5%
From 52-week high-5.6%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MLYSMineralys Therapeutics Inc.$21.00-5.53%$1.9B
PVLAPalvella Therapeutics Inc.$128.51-4.37%$1.9B
URGNUroGen Pharma Ltd.$38.26-0.05%$1.9B
ADRXADARx Pharmaceuticals Inc.$17.70-1.50%$1.9B
LKFTLakefront Biotherapeutics$29.05-1.76%$1.9B
AGIOAgios Pharmaceuticals Inc.$30.21-1.98%$1.8B
VERAVera Therapeutics Inc.$26.79-3.35%$1.9B
SDGRSchrodinger Inc.$25.89-0.08%$1.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier